FdaApplication
NDA 207356
Identifiers
- fda_app_no: NDA207356
Properties
| Property | Value |
|---|---|
| applicant_name | INSMED INC |
| application_type | NDA |
| approval_date | 2018-09-28 |
Revenue by product
ARIKAYCE KIT
| Period | Revenue |
|---|---|
| Q2 2026 | $116.3M |
| Q1 2026 | $98.1M |
| Q4 2025 | $119.2M |
| Q3 2025 | $114.3M |
| Q2 2025 | $107.4M |
| Q1 2025 | $92.8M |
| Q4 2024 | $104.4M |
| Q3 2024 | $93.4M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ARIKAYCE KIT | AMIKACIN SULFATE | EQ 590MG BASE/8.4ML | SUSPENSION, LIPOSOMAL;INHALATION |
1 product